Sarepta has key catalysts in 2023, says Cantor Fitzgerald

Cantor Fitzgerald analyst Kristen Kluska reiterates an Overweight rating on Sarepta Therapeutics with a $174 price target as part of her "New Year’s Countdown" of 10 stocks with 2023 catalysts that should be on investors’ radar. In the coming year, she expects that most investor focus will be on regulatory decisions behind Sarepta’s AAVrh74-based gene therapy encoding micro-dystrophin, SRP-9001, which has a regulatory action date of May 29, Kluska tells investors. It is her expectation that "many patients are likely to utilize this treatment" if approved, the analyst added.